Attached files

file filename
EX-10.52 - EMPLOYMENT AGREEMENT WITH DOUGLAS PLASSCHE - ELITE PHARMACEUTICALS INC /NV/f10k2021ex10-52_elitepharma.htm
10-K - ANNUAL REPORT - ELITE PHARMACEUTICALS INC /NV/f10k2021_elitepharma.htm
EX-32.2 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/f10k2021ex32-2_elitepharma.htm
EX-32.1 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/f10k2021ex32-1_elitepharma.htm
EX-31.2 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/f10k2021ex31-2_elitepharma.htm
EX-31.1 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/f10k2021ex31-1_elitepharma.htm
EX-10.54 - JULY 29, 2019 AMENDMENT TO THE LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT BETWEE - ELITE PHARMACEUTICALS INC /NV/f10k2021ex10-54_elitepharma.htm
EX-10.53 - JUNE 21, 2019 RETENTION AGREEMENT WITH DOUGLAS PLASSCHE - ELITE PHARMACEUTICALS INC /NV/f10k2021ex10-53_elitepharma.htm

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the following documents of our report dated June 14, 2021, relating to the consolidated financial statements of Elite Pharmaceuticals, Inc. and Subsidiary, included in the Annual Report on Form 10-K of the Company for the year ended March 31, 2021.

 

Registration Statement No. 333-197694 on Form S-8

Registration Statement No. 333-163907 on Form S-8

Registration Statement No. 333-132140 on Form S-8

Registration Statement No. 333-118524 on Form S-8

Registration Statement No. 333-239847 on Form S-3

 

/s/ Buchbinder Tunick & Company LLP

 

Little Falls, New Jersey

 

June 14, 2021